Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works
AACR-2022 NI-3201 CD28 bispecific antibody platform

AACR-2022 NI-3201 CD28 bispecific antibody platform

AACR Annual Meeting 202- Sara Majocchi -


Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes

The American Association for Cancer Research (AACR) will host its Annual Meeting April 8-13, 2022. Light Chain Bioscience is very pleased to have Sara Majocchi attend in-person.

Sara will be presenting a poster (#2884) describing Light Chain Bioscience's CD28-bispecific antibody platform.

“Optimized CD28 bispecific antibodies for targeted activation of T cells within the tumor microenvironment” will be exposed and presented on April 12 between 9:00 a.m -12:30 p.m.

Read poster - Poster section 37 [PDF]:

AACR 2022 NI 3201 CD28 bispecific antibody platform 3201


Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body


Read more

LinkedIn